Merck Announces $6.7 Billion Acquisition of Terns Pharmaceuticals
Published on · Source: investors.com
AI Summary
Summarized by AI from the source belowMerck has announced a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion. This acquisition is seen as part of Merck's strategy to expand its oncology portfolio and strengthen its pipeline. The deal aligns with Merck's focus on innovative drug development. The transaction is expected to close in the fourth quarter of 2023, pending regulatory approvals.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Merck & Co. Inc. (MRK)
Merck is a global pharmaceutical company best known for its oncology, vaccine, and animal-health franchises.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier MRK news
MRK stock page and all news →Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
